StockData
Impact BioMedical Inc. logo

Impact BioMedical Inc. (IBO) stock

IBONYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/30
$3.06+0.38 (+14.18%)

Close on Oct 19, 2026Market cap $329.93MP/E –Yield –

Impact BioMedical gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

Impact BioMedical's gross profit for the twelve months ending Dec 31, 2025 was -$392.00K. For fiscal 2025 it was -$392.00K.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$392.00K–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$2.00K–
Q4 FY2025Dec 31, 2025-$415.00K–
Q3 FY2025Sep 30, 2025$17.00K–
Q2 FY2025Jun 30, 2025$6.00K–

More Impact BioMedical figures

See a number that looks wrong?